Diversity is a pathway to excellence, BIO’s King says

BIO’s top priorities are implementation of the Inflation Reduction Act, FDA’s accelerated approval pathway, capital formation, and diversity, equity and inclusion issues, Rachel King, the trade association’s interim CEO, told The BioCentury Show.

In a wide-ranging interview, King discussed public perceptions of the biotech industry, the need to find and nurture political champions, and the pressing concerns of BIO’s members. Among the most pressing, she said, are the Medicare drug price-setting provisions of the IRA, which “do not align with patient needs.” BIO is working to build the case for changes to the law. She acknowledged that this will take time given the difficulty of passing any legislation in the current political environment.  ...